About Harvard Bioscience, Inc.
https://www.harvardbioscience.comHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally.
CEO
John Duke
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-11-04 | Forward | 1319:1000 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
AMH EQUITY LTD
Shares:4.05M
Value:$2.29M
BLACKROCK INC.
Shares:2.84M
Value:$1.61M
HARVEY PARTNERS, LLC
Shares:2.05M
Value:$1.16M
Summary
Showing Top 3 of 87
About Harvard Bioscience, Inc.
https://www.harvardbioscience.comHarvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $20.59M ▲ | $11.82M ▲ | $-1.23M ▲ | -5.98% ▲ | $-0.03 ▲ | $1.16M ▲ |
| Q2-2025 | $20.45M ▼ | $11.19M ▼ | $-2.28M ▲ | -11.16% ▲ | $-0.05 ▲ | $155K ▲ |
| Q1-2025 | $21.77M ▼ | $61.85M ▲ | $-50.34M ▼ | -231.19% ▼ | $-1.14 ▼ | $-48.34M ▼ |
| Q4-2024 | $24.56M ▲ | $14M ▼ | $18K ▲ | 0.07% ▲ | $0 ▲ | $3.2M ▲ |
| Q3-2024 | $21.97M | $14.64M | $-4.8M | -21.86% | $-0.11 | $-1.82M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $6.82M ▼ | $77.99M ▼ | $63.92M ▼ | $14.07M ▼ |
| Q2-2025 | $7.44M ▲ | $80.09M ▲ | $64.36M ▼ | $15.73M ▲ |
| Q1-2025 | $5.55M ▲ | $79.8M ▼ | $64.97M ▲ | $14.84M ▼ |
| Q4-2024 | $4.11M ▼ | $126.64M ▼ | $63.3M ▼ | $63.34M ▼ |
| Q3-2024 | $4.57M | $131.24M | $65.92M | $65.32M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-1.23M ▲ | $830K ▼ | $-348K ▼ | $-1.02M ▲ | $-625K ▼ | $623K ▼ |
| Q2-2025 | $-2.28M ▲ | $2.75M ▼ | $-233K ▲ | $-1.26M ▼ | $1.9M ▲ | $2.52M ▲ |
| Q1-2025 | $-50.34M ▼ | $2.99M ▲ | $-683K ▼ | $-1.2M ▲ | $1.44M ▲ | $2.47M ▲ |
| Q4-2024 | $18K ▲ | $1.73M ▲ | $-466K ▲ | $-1.36M ▼ | $-461K ▼ | $1.26M ▲ |
| Q3-2024 | $-4.8M | $-842K | $-1.11M | $2.1M | $521K | $-1.95M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Instruments Equipment Software and Accessories | $40.00M ▲ | $20.00M ▼ | $20.00M ▲ | $20.00M ▲ |
 Service Maintenance and Warranty Contracts | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Revenue by Geography
| Region | Q4-2024 | Q2-2025 | Q1-2025 | Q3-2025 |
|---|---|---|---|---|
 Americas other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Asia Other | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 CHINA | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 EMEA | $0 ▲ | $10.00M ▲ | $10.00M ▲ | $10.00M ▲ |
 UNITED STATES | $20.00M ▲ | $10.00M ▼ | $10.00M ▲ | $10.00M ▲ |
 Greater China | $10.00M ▲ | $0 ▼ | $0 ▲ | $0 ▲ |
CEO
John Duke
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2013-11-04 | Forward | 1319:1000 |
ETFs Holding This Stock
Summary
Showing Top 2 of 12
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
AMH EQUITY LTD
Shares:4.05M
Value:$2.29M
BLACKROCK INC.
Shares:2.84M
Value:$1.61M
HARVEY PARTNERS, LLC
Shares:2.05M
Value:$1.16M
Summary
Showing Top 3 of 87